Literature Collection

Magnifying Glass
Collection Insights

11K+

References

9K+

Articles

1500+

Grey Literature

4600+

Opioids & SU

The Literature Collection contains over 11,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More

Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).

Enter Search Term(s)
Year
Sort by
Order
Show
12581 Results
2041
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)
Type: Journal Article
Authors: J. S. Potter, E. N. Marino, M. P. Hillhouse, S. Nielsen, K. Wiest, C. P. Canamar, J. A. Martin, A. Ang, R. Baker, A. J. Saxon, W. Ling
Year: 2013
Publication Place: United States
Abstract: OBJECTIVE: The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (injector or non-injector) of opioid use. METHOD: A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. RESULTS: Non-opioid substance dependence diagnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated injectors from non-injectors. Further, injectors were more likely to be using at end of treatment compared with non-injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-injectors were more likely than injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. CONCLUSIONS: Findings indicate that substance use severity differentiates heroin users from OA users and injectors from non-injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users.
Topic(s):
Opioids & Substance Use See topic collection
2042
Buprenorphine/Naloxone for Opioid Use Disorder Among Alaska Native and American Indian People
Type: Journal Article
Authors: Kate M. Lillie, Jennifer Shaw, Kelley J. Jansen, Michelle M. Garrison
Year: 2021
Publication Place: Baltimore, Maryland
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
2043
Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments
Type: Journal Article
Authors: K. D. Stone, K. Scott, B. R. Holroyd, E. Lang, K. Yee, N. Taghizadeh, J. Deol, K. Dong, J. Fanaeian, M. Ghosh, K. Low, M. Ross, R. Tanguay, P. Faris, N. Day, P. McLane
Year: 2023
Topic(s):
Opioids & Substance Use See topic collection
2044
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors
Type: Journal Article
Authors: Lynn E. Sullivan, Brent A. Moore, Marek C. Chawarski, Michael V. Pantalon, Declan Barry, Patrick G. O'Connor, Richard S. Schottenfeld, David A. Fiellin
Year: 2008
Topic(s):
Opioids & Substance Use See topic collection
2045
Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals
Type: Journal Article
Authors: F. D. Law, A. M. Diaper, J. K. Melichar, S. Coulton, D. J. Nutt, J. S. Myles
Year: 2017
Publication Place: United States
Abstract: Buprenorphine/naloxone, methadone and lofexidine are medications with utility in the treatment of opiate withdrawal. We report the first randomised controlled trial to compare the effects of these two medications on withdrawal symptoms and outcome during opiate induction/stabilisation and detoxification. A double-blind randomised controlled trial was conducted in an outpatient satellite clinic of a specialist drug service. Eighty opiate dependent individuals meeting DSM-IV criteria for opiate dependence, using (1/2) g heroin smoked/chased or (1/4) g heroin injected or 30mg methadone, with 3 years of opioid dependency, underwent a short-term opiate treatment programme involving induction/stabilisation on methadone 30mg or buprenorphine/naloxone 4mg/1mg, followed by detoxification (where the methadone group was assisted by lofexidine). The main outcome measures were urine drug screens for opiates and withdrawal and craving questionnaires. There were no overall differences in positive urine drug screens and drop-outs during any phase of the study. During induction/stabilisation, withdrawal symptoms subsided more slowly for buprenorphine/naloxone than for methadone, and craving was significantly higher in the buprenorphine/naloxone group ( p<0.05, 95% confidence interval -3.5, -0.38). During detoxification, withdrawal symptoms were significantly greater and the peak of withdrawal was earlier for the methadone/lofexidine group than the buprenorphine/naloxone group ( p<0.01, 95% confidence interval 3.0, 8.3). Methadone/lofexidine and buprenorphine/naloxone had comparable outcomes during rapid outpatient stabilisation and detoxification in low dose opiate users.
Topic(s):
Opioids & Substance Use See topic collection
2046
Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals
Type: Journal Article
Authors: F. D. Law, A. M. Diaper, J. K. Melichar, S. Coulton, D. J. Nutt, J. S. Myles
Year: 2017
Publication Place: United States
Abstract: Buprenorphine/naloxone, methadone and lofexidine are medications with utility in the treatment of opiate withdrawal. We report the first randomised controlled trial to compare the effects of these two medications on withdrawal symptoms and outcome during opiate induction/stabilisation and detoxification. A double-blind randomised controlled trial was conducted in an outpatient satellite clinic of a specialist drug service. Eighty opiate dependent individuals meeting DSM-IV criteria for opiate dependence, using (1/2) g heroin smoked/chased or (1/4) g heroin injected or 30mg methadone, with 3 years of opioid dependency, underwent a short-term opiate treatment programme involving induction/stabilisation on methadone 30mg or buprenorphine/naloxone 4mg/1mg, followed by detoxification (where the methadone group was assisted by lofexidine). The main outcome measures were urine drug screens for opiates and withdrawal and craving questionnaires. There were no overall differences in positive urine drug screens and drop-outs during any phase of the study. During induction/stabilisation, withdrawal symptoms subsided more slowly for buprenorphine/naloxone than for methadone, and craving was significantly higher in the buprenorphine/naloxone group ( p<0.05, 95% confidence interval -3.5, -0.38). During detoxification, withdrawal symptoms were significantly greater and the peak of withdrawal was earlier for the methadone/lofexidine group than the buprenorphine/naloxone group ( p<0.01, 95% confidence interval 3.0, 8.3). Methadone/lofexidine and buprenorphine/naloxone had comparable outcomes during rapid outpatient stabilisation and detoxification in low dose opiate users.
Topic(s):
Opioids & Substance Use See topic collection
2047
Burden and nutritional deficiencies in opiate addiction- systematic review article
Type: Journal Article
Authors: S. Nabipour, Ayu Said, Hussain Habil
Year: 2014
Publication Place: Iran
Abstract: Addiction to the illicit and prescribed use of opiate is an alarming public health issue. Studies on addictive disorders have demonstrated severe nutritional deficiencies in opiate abusers with behavioral, physiological and cognitive symptoms. Opiate addiction is also link with a significant number of diseases including Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) and other blood borne diseases generally stem from the use of needles to inject heroin. The use of medication assisted treatment for opioid addicts in combination with behavioural therapies has been considered as a highly effective treatment. Methadone is a long-lasting mu-opioid agonist and a pharmacological tool which attenuates withdrawal symptoms effectively replacement therapies. This review article aims to explain opiate addiction mechanisms, epidemiology and disease burden with emphasis on dietary and nutritional status of opiate dependent patients in methadone maintenance therapy.
Topic(s):
Opioids & Substance Use See topic collection
2048
Burden of medical illness in drug- and alcohol-dependent persons without primary care
Type: Journal Article
Authors: I. De Alba, J. H. Samet, R. Saitz
Year: 2004
Topic(s):
General Literature See topic collection
2049
Burnout among behavioral health providers in integrated care settings
Type: Journal Article
Authors: M. Zubatsky, C. Runyan, S. Gulotta, J. R. Knight, J. D. Pettinelli
Year: 2020
Publication Place: United States
Topic(s):
Education & Workforce See topic collection
,
Measures See topic collection
2050
Burnout in Primary Care
Type: Web Resource
Authors: Agency for Healthcare Research and Quality
Year: 2023
Publication Place: Rockville, MD
Topic(s):
Education & Workforce See topic collection
,
Grey Literature See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

2051
Burnout in Primary Care—Assessing and Addressing it in Your Practice
Type: Web Resource
Authors: Agency for Healthcare Resarch and Quality
Year: 2023
Publication Place: Rockville, MD
Topic(s):
Grey Literature See topic collection
,
Education & Workforce See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

2052
C-L case conference: Chronic psychosis managed in collaborative care
Type: Journal Article
Authors: Molly Howland, Denise Chang, Anna Ratzliff, Katherine Palm-Cruz
Year: 2021
Topic(s):
Education & Workforce See topic collection
,
Healthcare Disparities See topic collection
2053
C2C Roadmap to Behavioral Health
Type: Web Resource
Authors: Centers for Medicare and Medicaid Services
Year: 2024
Publication Place: Baltimore, MD
Topic(s):
Opioids & Substance Use See topic collection
,
Grey Literature See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

2054
CA Bridge Study Finds Emergency Department Buprenorphine Linked to Sustained Opioid Use Disorder Treatment
Type: Report
Authors: CA Bridge
Year: 2024
Publication Place: Oakland, CA
Topic(s):
Opioids & Substance Use See topic collection
,
Grey Literature See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

2055
CADTH Health Technology Review
Type: Book Chapter
Year: 2025
Publication Place: Ottawa (ON)
Abstract:

WHAT IS ALTERNATE LEVEL OF CARE? • Alternate level of care (ALC) is a designation used and applied by clinical staff to the portion of a patient’s hospital stay when the patient is occupying a bed in a facility (e.g., acute care; mental health; rehabilitation; and chronic, intermediate, or complex continuing care settings) but they no longer require the intensity of resources or services provided in that care setting. WHAT ARE THE CHALLENGES? • In 2022–2023, an estimated 6.2% of hospitalizations in Canada had an ALC component, with a provincial and territorial range of 1.0% to 8.3%. An estimated 17.0% of hospital days were for patients in ALC, with a provincial and territorial range of 6.8% to 26.1%. • Patients with an ALC designation may be more at risk of adverse events, hospital-acquired infections, mental and physical deterioration, and mortality. ALC bed days also contribute to higher hospital costs and system flow issues, including overcapacity, emergency department (ED) and hospital overcrowding, and prolonged wait times. • Patients of any age and any health condition may remain in hospital after their acute care needs have been met; however, the most common group of patients who are in ALC are older adults. • Determining whether a patient’s stay receives an ALC designation requires the application of the ALC definition while considering the individual patient’s context. There are many factors that influence whether a hospital stay will result in an ALC designation, including variations in patients, settings, and circumstances. • The ALC indicator was originally meant to capture unmet needs of patients. It is now predominantly a designation placed on a portion of patients’ hospital stays, and often patients are unaware of their ALC status and what it means. • The variation in ALC definitions and their application, as well as situational contexts such as the demographics of patients, ALC rates, and interventions, make it difficult to compare ALC between jurisdictions. WHAT DID WE DO? • To inform policy and decision-making in support of evidence-informed strategies to reduce the time people spend in ALC, we assess: o.. ALC definitions in Canada and how they are applied across jurisdictions; o.. reasons for ALC designation, including the reasons people with unmet needs receive ALC designation and remain in ALC in acute inpatient care settings and the relevant, related ethical considerations; o.. effectiveness and harms of published interventions to alleviate the ALC burden; o.. other interventions implemented in Canada and internationally that exist to help alleviate the ALC burden; o.. economic and resource considerations associated with ALC interventions to health systems and patients; o.. implementation considerations to identify facilitators of, and barriers to, implementation of ALC interventions. • Interventions were aligned with 3 categories: ALC avoidance (upstream), ALC patient flow (midstream), and ALC patient discharge (downstream). • To supplement findings from the evidence, review and to help describe the ALC landscape across Canada, we also conducted an analysis of real-world data. We developed an interactive dashboard that includes figures that describe ALC data by different provinces and territories in Canada, over time. • To support this work, we engaged people with personal and/or professional experience with ALC, caring for older adults as they age, or health care decision-making in Canada. We searched key information and data sources — including journal databases, trial registers, and websites — and conducted focused internet searches for relevant evidence on initiatives to reduce ALC. WHAT DID WE FIND? • Across the jurisdictions, ALC is defined in alignment with the Canadian Institute for Health Information (CIHI) definition as patients occupying a bed while no longer requiring the services provided by their admitting acute care facility or department as they wait for transfer to more appropriate care settings. Slight differences arise from the designation criteria and the code assignments for patients. • ALC designation involves assigning specific codes or criteria to reflect the change in a patient’s status and reasons for the designation. • ALC days are widely used as a performance indicator across jurisdictions to assess ALC, along with other metrics such as the percentage of hospitalized patients designated as ALC and the number of ALC beds occupied per day. • We found that individual sociodemographic and clinical factors, process and practice factors within and across acute and nonacute care settings, and structural factors contribute to ALC designations. We also found that multiple, intersecting factors that contribute to ALC can raise ethical considerations and present ethical dilemmas for patients, care partners, families, health care providers, and health systems in the context of ALC designations. • We examined evidence on the effectiveness of 6 multicomponent interventions that have been described in comparative studies in the published literature intended to alleviate the ALC burden in acute care hospital settings. Overall, there was very low–certainty evidence of the clinical benefits of these interventions: • The Humber River Health’s Humber’s Elderly Assess and Restore Team (HEART) program (a midstream-downstream intervention) and a step-down intermediate care unit for older patients who are hospitalized plus a 72-hour discharge target (a downstream intervention) may reduce ALC rates compared with usual care, but the evidence is very uncertain due to critical or serious risk of bias and indirectness. • The Sub-Acute Care for Frail Elderly (SAFE) Unit located in a long-term care [LTC] home in Ontario (a downstream intervention), vertical integration of care (a system-level intervention), and urgent and emergency care vanguards (a system-level intervention) may reduce ALC lengths of stay compared with usual care or no intervention, but the evidence is very uncertain due to critical risk of bias and indirectness. • Coordinated care planning based on the Health Links model (a system-level intervention) may make little to no difference on ALC lengths of stay compared to no intervention, but the evidence is very uncertain due to serious risk of bias and serious imprecision. • We also identified 11 noncomparative studies (that were not critically appraised) of the following: o.. six midstream interventions — increased step-down beds, specialized acute care space or service, and enhanced discharge planning; o.. two downstream interventions — transitional care units; o.. three system-level interventions — integrated care for older people and home-first strategies. • From the literature, we identified a total of 19 new and emerging interventions in Canada, 10 international interventions, and 2 international case studies. Interventions intended to help reduce ALC designation of patients, improve patient flow, facilitate patient discharge, and provide educational and practical guidance about ways to alleviate the ALC burden. • Findings from a survey conducted as part of our environmental scanning activities suggested that although most jurisdictions use the CIHI definition of ALC, there is variation in the type of staff who assign ALC codes, the uses of ALC data, and fees associated with ALC designation. Strategies to alleviate the ALC burden most often aim to reduce ALC length of stay, are typically set in hospitals, involve a wide range of clinical and nonclinical staff, and are frequently targeted toward older adults, people awaiting discharge to residential care, and people with complex needs. • Resource impacts should be considered with respect to the implementation of any strategies to alleviate the ALC burden, including those pertaining to set-up, management, and delivery of care, alongside careful consideration of coordination, flow between different strategies, and redistribution implications. We identified 1 Canadian economic evaluation on the cost-effectiveness of the SAFE Unit (a downstream intervention) compared with usual care to alleviate the ALC burden. The overall literature suggests that this and other strategies for alleviating ALC may be less costly, resulting in the opportunity to treat more patients at the required level of care and thus increase efficiency in the use of health care resources. • Key participants in the implementation of ALC interventions include patients, care partners, clinicians, support staff, government, administrators, and communities, suggesting everyone involved plays a role in the successful implementation of these interventions. • Care providers should consider the use of cross-sector integration, enhanced communication, and multidisciplinary collaboration, supported by high-quality data that are integrated with the flow of the patient through their health journey to inform decision-making to aid in successfully implementing of ALC interventions. • Implementation should be approached as a continuum where approaches are tailored to the needs and complexities of the individual patient while assessing the requirements to transition between each step of care. NEXT STEPS: • Our Health Technology Expert Review Panel will use the findings of this report to support deliberations that will result in the development of guidance to inform decisions around evidence-informed strategies and initiatives that could be considered to reduce the time patients spend with an ALC designation.

Topic(s):
HIT & Telehealth See topic collection
2056
California PCPs coordinate Medi-Cal behavioral health
Type: Journal Article
Authors: Stephanie Skernivitz
Year: 2010
Topic(s):
Financing & Sustainability See topic collection
,
Healthcare Policy See topic collection
2057
California primary care, mental health, and substance use services integration policy initiative
Type: Report
Year: 2009
Publication Place: Sacramento, CA
Topic(s):
Grey Literature See topic collection
,
Healthcare Disparities See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

2058
California primary care, mental health, and substance use services integration policy initiative Volume III: Examples for Dissemination
Type: Government Report
Year: 2009
Publication Place: Sacramento, CA
Topic(s):
Grey Literature See topic collection
,
Healthcare Policy See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

2059
California primary care, mental health, and substance use services integration policy initiative: Volume II - Working Papers
Type: Government Report
Year: 2009
Publication Place: Sacramento, CA
Topic(s):
Education & Workforce See topic collection
,
Financing & Sustainability See topic collection
,
HIT & Telehealth See topic collection
,
Healthcare Policy See topic collection
,
Grey Literature See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

2060
Campaign to Stop Youth Opioid Abuse
Type: Web Resource
Authors: Truth Initiative
Year: 2018
Topic(s):
Grey Literature See topic collection
,
Opioids & Substance Use See topic collection
Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.